You are here

Rebif®

(Recombinant interferon beta), identical to the native molecule and registered for the treatment of multiple sclerosis and several viral diseases, licensed to Inter-Lab Ltd., a Serono company.  

  • Indicated for Multiple Sclerosis Rebif is a recombinant interferon beta 1a.
  • Rebif is marketed worldwide by Merck Serono.
  • 1982: Licensed to Interpharm.
  • 2007 Sales: Euro 1.2 Billion
  • 2007 Market share: 32%